Keeping you up to date on recent developments in orthopedics, including: New drug shown to improve bone growth in children with achondroplasia; Failure to calibrate for ethnicity in fracture epidemiology would do more harm than good; Muscle aging: Stronger for longer; After Medicaid expansion, 'unmet need' for joint replacement surgery.
According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), drug-induced liver injury (DILI) is the leading cause of acute liver failure in the U.S. It is also a leading cause of drug failure in clinical trials. Now, researchers have used liver organoids to develop a polygenic risk score that could predict the risk of liver toxicity for multiple different drugs, regardless of the underlying mechanism.
BioWorld looks at translational medicine, including: Angiopoietin trouble can lead to lymphedema; Toxicity, infectivity separate issues for prion protein.
An Australian study led by University of Melbourne scientists has identified a previously unknown role for the hepatokine, sparc-related modular calcium-binding protein 1 (SMOC1), in suppressing hepatic glucose production.
Keeping you up to date on recent developments in oncology, including: Algorithm improves prediction of hepatocellular carcinoma following hepatitis-driven cirrhosis; MTOR-targeting metabolite discovered; Dartmouth’s Thayer School wins NIH grant.
Keeping you up to date on recent developments in neurology, including: Sleep quality linked to onset; progression of Alzheimer's; Using magnetic resonance elastography to detect epilepsy; How can hearing loss cause dementia?
BioWorld looks at translational medicine, including: MTOR-targeting metabolite discovered; AKG for A-OK aging; Benzodiazepine and barbiturate binding to GABA-A; Giving misfolded proteins a second chance; Agrin-culture grows cartilage; SCAD vs. plaques in heart attacks.
An Australian study led by University of Melbourne scientists has identified a previously unknown role for the hepatokine, sparc-related modular calcium-binding protein 1 (SMOC1), in suppressing hepatic glucose production. The investigators reported their results in the Sept. 2, 2020, edition of Science Translational Medicine.
Researchers at City of Hope have used a combination of oncolytic virus and CD19-targeting CAR T cells to first force expression of CD19 on tumor cells and then hunt down those cells, eradicating tumors in immunocompetent mouse models and endowing them with immunity to later re-administration of tumor cells.
RSS
